Growth hormone secretagogues
Ipamorelin
Written by the Elevate Clinical Team
Citations independently verified against PubMed, ClinicalTrials.gov, and FDA sources on . Independent clinical review pending.
A selective growth-hormone secretagogue studied for GH release without meaningful cortisol or prolactin rise.
What it is
Ipamorelin acts on the ghrelin receptor to trigger growth-hormone release. Its research appeal is selectivity: compared with older secretagogues it produces relatively little cortisol, prolactin or appetite response, which is why it appears so often in recovery-oriented protocols.
What it's studied for
- Pulsatile growth-hormone release
- Recovery, sleep depth and lean-mass signaling
- Post-operative gut-motility research
How it's used in practice
- Frequently paired with a GHRH analog such as CJC-1295 for a larger combined pulse
- Typically dosed away from food because insulin blunts the GH response
What you should know before asking about it
- Availability through licensed compounding pharmacies has changed over time and continues to
- Contraindicated with active malignancy
- Prohibited in competitive sport
Frequently asked questions.
- What is Ipamorelin?
- Ipamorelin acts on the ghrelin receptor to trigger growth-hormone release. Its research appeal is selectivity: compared with older secretagogues it produces relatively little cortisol, prolactin or appetite response, which is why it appears so often in recovery-oriented protocols.
- What is Ipamorelin studied for?
- Published and ongoing research looks at pulsatile growth-hormone release; recovery, sleep depth and lean-mass signaling; post-operative gut-motility research. These are areas of study, not promised outcomes.
- Is Ipamorelin FDA-approved?
- Ipamorelin is not FDA-approved as a finished product. It is prepared by licensed, FDA-registered compounding pharmacies and can be dispensed only on a prescription written after a physician evaluation.
- How is Ipamorelin typically used?
- Frequently paired with a GHRH analog such as CJC-1295 for a larger combined pulse Typically dosed away from food because insulin blunts the GH response Any specific dose, frequency or duration comes from a prescription written for you after labs — never from this page.
- What are the risks and unknowns with Ipamorelin?
- Availability through licensed compounding pharmacies has changed over time and continues to Contraindicated with active malignancy Prohibited in competitive sport
Sources
- 1.Published literature on Ipamorelin— PubMed, U.S. National Library of Medicine
- 2.Compounding and the FDA: questions and answers— U.S. Food & Drug Administration
- 3.Bulk drug substances nominated for use in compounding under section 503A— U.S. Food & Drug Administration
- 4.Test directory and patient service center locator— Quest Diagnostics
About this page
Written by the Elevate Clinical Team
Citations independently verified against PubMed, ClinicalTrials.gov, and FDA sources on . Independent clinical review pending. Educational content only — not medical advice, not a diagnosis, and not an offer to sell any prescription product.
This page is educational reference material. It is not medical advice, not a diagnosis, and not an offer to sell any product. Prescription therapies are dispensed only through licensed, FDA-registered compounding pharmacies after a physician evaluation. Compounds identified as research use only are not FDA-approved, are not prescribed as medical care, and are not intended for human or animal consumption. Availability, formulations and regulatory status change over time.
More in Growth hormone secretagogues
Sermorelin
A growth-hormone-releasing hormone analog that prompts your own pituitary output rather than replacing it.
CJC-1295
A GHRH analog with extended half-life, studied to raise baseline growth-hormone and IGF-1 signaling.
Tesamorelin
An FDA-approved GHRH analog with the strongest clinical evidence of any peptide for reducing visceral adipose tissue.